NanoBio Corporation Announces Development of Nasal Vaccine for the Prevention of Urinary Tract Infections in Collaboration with the University of Michigan
ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio Corporation today announced a licensing agreement with the University of Michigan that provides NanoBio with rights to an antigen that has been shown to prevent urinary tract infections (UTIs) following intranasal vaccination.